191 related articles for article (PubMed ID: 28271699)
1. Individualization of controlled ovarian stimulation in vitro fertilization using ovarian reserve markers.
Grisendi V; La Marca A
Minerva Ginecol; 2017 Jun; 69(3):250-258. PubMed ID: 28271699
[TBL] [Abstract][Full Text] [Related]
2. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice.
La Marca A; Sunkara SK
Hum Reprod Update; 2014; 20(1):124-40. PubMed ID: 24077980
[TBL] [Abstract][Full Text] [Related]
3. How to personalize ovarian stimulation in clinical practice.
Sighinolfi G; Grisendi V; La Marca A
J Turk Ger Gynecol Assoc; 2017 Sep; 18(3):148-153. PubMed ID: 28890430
[TBL] [Abstract][Full Text] [Related]
4. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
[TBL] [Abstract][Full Text] [Related]
5. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
[TBL] [Abstract][Full Text] [Related]
6. Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
Minerva Ginecol; 2017 Jun; 69(3):225-232. PubMed ID: 27352270
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mullerian Hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles.
Tolikas A; Tsakos E; Gerou S; Prapas Y; Loufopoulos A
Hum Fertil (Camb); 2011 Dec; 14(4):246-53. PubMed ID: 22088130
[TBL] [Abstract][Full Text] [Related]
8. Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction.
Brodin T; Hadziosmanovic N; Berglund L; Olovsson M; Holte J
Acta Obstet Gynecol Scand; 2015 Oct; 94(10):1056-63. PubMed ID: 26184379
[TBL] [Abstract][Full Text] [Related]
9. Anti-Müllerian hormone dynamics during GNRH-antagonist short protocol for IVF/ICSI in women with varying ovarian reserve levels.
Melado Vidales L; Fernández-Nistal A; Martínez Fernández V; Verdú Merino V; Bruna Catalán I; Bajo Arenas JM
Minerva Ginecol; 2017 Apr; 69(2):128-134. PubMed ID: 27310675
[TBL] [Abstract][Full Text] [Related]
10. Nomogram to predict FSH starting dose in poor ovarian response women in progestin primed ovarian stimulation protocol.
Wu S; Li Y; Wu G; Wu H
BMC Womens Health; 2023 Apr; 23(1):202. PubMed ID: 37118751
[TBL] [Abstract][Full Text] [Related]
11. Basal serum level of Δ4-androstenedione reflects the ovaries' ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response.
Garzia E; Galiano V; Guarnaccia L; Marfia G; Murru G; Guermandi E; Riparini J; Sulpizio P; Marconi AM
J Assist Reprod Genet; 2022 Aug; 39(8):1917-1926. PubMed ID: 35759063
[TBL] [Abstract][Full Text] [Related]
12. Association of blood groups with ovarian reserve and outcome of in vitro fertilization treatment.
Awartani K; Al Ghabshi R; Al Shankiti H; Al Dossari M; Coskun S
Ann Saudi Med; 2016; 36(2):116-20. PubMed ID: 27031784
[TBL] [Abstract][Full Text] [Related]
13. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve.
Di Paola R; Garzon S; Giuliani S; Laganà AS; Noventa M; Parissone F; Zorzi C; Raffaelli R; Ghezzi F; Franchi M; Zaffagnini S
Arch Gynecol Obstet; 2018 Nov; 298(5):1029-1035. PubMed ID: 30242498
[TBL] [Abstract][Full Text] [Related]
14. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
[TBL] [Abstract][Full Text] [Related]
15. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
Majumder K; Gelbaya TA; Laing I; Nardo LG
Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
[TBL] [Abstract][Full Text] [Related]
16. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection.
Polyzos NP; Tournaye H; Guzman L; Camus M; Nelson SM
Fertil Steril; 2013 Aug; 100(2):430-7. PubMed ID: 23668992
[TBL] [Abstract][Full Text] [Related]
17. The cutoff values of serum AMH levels and starting recFSH doses for the individualization of IVF treatment strategies.
Özcan P; Fiçicioğlu C; Ateş S; Can MG; Kaspar Ç; Akçin O; Yesiladali M
Gynecol Endocrinol; 2017 Jun; 33(6):467-471. PubMed ID: 28277814
[TBL] [Abstract][Full Text] [Related]
18. Ovarian reserve and in vitro fertilization cycles outcome according to women smoking status and stimulation regimen.
Freour T; Masson D; Dessolle L; Allaoua D; Dejoie T; Mirallie S; Jean M; Barriere P
Arch Gynecol Obstet; 2012 Apr; 285(4):1177-82. PubMed ID: 22183426
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of anti-Müllerian hormone-tailored ovarian stimulation protocols in in vitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age.
Liao CC; Lee RK; Lin SY; Lin MH; Hwu YM
Taiwan J Obstet Gynecol; 2016 Apr; 55(2):239-43. PubMed ID: 27125408
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials.
Nelson SM; Klein BM; Arce JC
Fertil Steril; 2015 Apr; 103(4):923-930.e1. PubMed ID: 25624196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
